Nuestra misión en la Fundación (Angiogenesis Foundation) es mejorar la salud en el mundo a través de la educación y el cabildeo empoderando a los pacientes para tener un rol activo en la lucha contra la pérdida de visión. Trabajamos con pacientes con EMD, sus defensores y prestadores de salud de todo el mundo para difundir el conocimiento sobre los tratamientos anti-VEGF para EMD con el propósito de mejorar los resultados.
Busque un Especialista de Retina
Actualización de los medios
The Science of DME via Facebook: It's almost the end of Low Vision Awareness Month, so please visit Look To Your Future, a new resource to help you take care of your eyes. Read patient stories, educate yourself on wet AMD and DME and find links to helpful patient organizations:
www.LookToYourFuture.com - 12 months ago
The Science of DME via Facebook: In a study published online by JAMA Ophthalmology, Gwyneth Rees, Ph.D., of the University of Melbourne, Australia, and colleagues examined the association between severity of diabetic retinopathy and diabetic macular edema with symptoms of depression and anxiety in adults with diabetes. - 2 years ago
The Science of DME via Facebook: This roundtable discussion, which took place during the 2015 annual meeting of the American Academy of Ophthalmology, outlines the current protocols used to treat DME and provides clinical opinions about selecting and treating with an appropriate anti-VEGF therapy.
It is moderated by Peter K. Kaiser, MD (Digital Optical Coherence Tomography Reading Center at Cleveland Clinic Cole Eye Institute; Cole Eye Institute) and features discussion from Dr. Stephan Michels, MD, MBA (University of Zurich; Triemli Hospital), Edoardo Midena, MD (European Board of Ophthalmology; University Hospital in Padova), John W. Kitchens, MD (Retina Associates of Kentucky; Kentucky Academy of Eye Physicians and Surgeons), Jonathan L. Prenner, MD (NJ Retina; Rutgers Robert Wood Johnson Medical School), Carl D. Regillo, MD, FACS (Retina Service at Wills Eye Hospital; Thomas Jefferson University), and Elias Reichel, MD (New England Eye Center in Massachusetts; Tufts University School of Medicine). - 2 years ago
The Science of DME via Facebook: Here, study authors present the first reported case of improvement of DME in the untreated fellow eye with injection of intravitreal aflibercept.
Aflibercept is an anti-vascular endothelial growth factor (VEGF) agent that has been approved for intravitreal injection for the treatment of diabetic macular edema (DME) in the United States, the European Union, Australia, and Japan.
There are multiple reports of treatment effect, measured by reduction of central foveal thickness (CFT) and improvement in visual acuity, in the untreated fellow eye with intravitreal injection of other anti-VEGF agents, including bevacizumab and ranibizumab. - 2 years ago
The Science of DME via Facebook: New research shows that Darapladib, a heart disease drug, could actually be used treat diabetic macular edema.
Scientists at Queen's University, Belfast and University College London (UCL) have found that the drug could reduce the need for injections, which is what diabetic macular edema patients are normally treated with.
Diabetic eye macular edema occurs in roughly seven per cent of patients with diabetes, who may have to be injected directly into the eye every four to six weeks with anti-VEGF drugs (anti-vascular endothelial growth factor). But the tablet version of Darapladib could limit the need for these injections. - 2 years ago
The Science of DME via Facebook: Eye complications are common among those with #diabetes, yet with proper care, these complications are preventable and, if they occur, more treatable than ever. In recent years, a new class of therapy called #VEGF inhibitors, which target the vascular endothelial growth factor, has emerged to treat ocular conditions associated with diabetes, including diabetic macular edema (#DME).
The American Journal of Managed Care recently convened an expert panel for a Peer Exchange, “Diabetes-Related Complications: a Focus on Diabetic Macular Edema.” Experts discussed new therapeutic options in DME, the importance of screening persons with diabetes for eye complications, and the factors that payers consider when evaluating the value of new therapy. - 2 years ago
The Science of DME via Facebook: Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.
Now a new report describes an initial experience converting from therapy with ranibizumab or bevacizumab to aflibercept. Although only a small study — researchers included 50 eyes of 37 patients — this practice led to significant anatomical improvement in the macular edema but did not significantly improve visual acuity or reduce intraocular pressure in the short term. - 2 years ago
The Science of DME via Facebook: #Didyouknow that evidence from NEI-supported investigators demonstrates that omega-3 fatty acids may prevent eye diseases caused by proliferative retinopathies and keep our eyes healthy? Cold-water fish like tuna, salmon, and mackerel are plentiful in fatty acids like DHA and EPA.
Watch #U2's The Edge to learn more about disease preventing foods and to learn about the work of the Angiogenesis Foundation at bit.ly/EatToBeat - 2 years ago
The Science of DME via Facebook: A study was recently conducted and found that saliva was shown to be a feasible alternative sample source for diabetic retinopathy biomarkers. The aim of the study was to determine the changes in protein expression in 2 different stages of diabetic retinopathy with type-2 diabetes mellitus. http://ow.ly/4n4Jya - 2 years ago
The Science of DME via Facebook: An association has been found between a defective myogenic response and early, accelerated development of retinopathy in patients with type 1 diabetes. Scientists at the Massachusetts Eye and Ear and Schepens Eye Research Institute state that these findings “identify one mechanism to explain why some patients develop diabetic retinopathy sooner than others. Furthermore, the research also provides a target for future study, which may lead to therapies to delay or prevent the development of accelerated onset diabetic retinopathy.”
http://www.genengnews.com/gen-news-highlights/biomarker-linked-to-rapid-onset-diabetic-retinopathy/81252558/?kwrd=defective%20myogenic%20response%20and%20early,%20accelerated%20development%20of%20retinopathy - 2 years ago
The Science of DME via Facebook: Most often, vision loss related to diabetes is said to be due to blood vessel damage in and around the retina. However, according to scientists at Washington University in St. Louis “new research indicates that much of that vision loss may result from nerve cell injury that occurs long before any blood vessels are damaged.”
http://ow.ly/105xGo - 2 years ago
By continuing, you will open a new tab to view search results presented by the American Society of Retina Specialists (ASRS) website.
The ASRS site is not controlled by or affiliated with ScienceofDME.org.